Another strategy for intracellular targeting instead leverages native cell surface receptor-ligand interactions and has found broad application in enzyme replacement therapies for lysosomal storage diseases (30, 32, 44, 76–78). The gene discussed is CD177; the disease is lysosomal storage disease.